JJJamaal C. Jackson

Jamaal C. Jackson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jamaal C. Jackson has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tissue Factor Expression in Penile Squamous Cell Carcinoma: A Potential Marker of HPV-Independent Disease

    by Jamaal C. Jackson, Andrew C. Johns, Leticia Campos Clemente, Christopher M. Manuel, Wei Qiao, Wei Lu, Khaja Khan, Luisa M. Solis Soto, Jad Chahoud, Priya Rao, et al.

    Background/Objectives: In a series of 33 patients with advanced penile squamous cell carcinoma (PSCC), we evaluated tissue factor (TF), TROP2, and nectin-4 protein expression as potential therapeutic targets. Expression levels of these proteins were also correlated to clinicopathological characteristics, including high-risk human papillomavirus (HPV), CDKN2A (p16) status, and aberrant p53 expression. Methods: A tissue microarray (TMA) was constructed with three cores per patient tumor (99 total cores). Anti-TF antibody staining was performed by immunohistochemistry, and H-scores for membrane and cytoplasm staining were assessed (range 0–300). The percentage of cores and patient tumors staining positive for TF (≥10% of tumor cells with at least 1+ intensity in cytoplasm and/or membrane) and H-scores were described and compared with HPV and p16 status. The association of TF expression with tumor grade, presence of metastatic disease, lymphovascular invasion (LVI), perineural invasion (PNI), aberrant p53 expression, recurrence-free survival (RFS), and cancer-specific survival (CSS) was assessed. Nectin-4 and TROP2 staining and their association with clinical/pathological data were determined in a similar manner. Results: TF staining was evident in 26 (81.3%) of the cohort and was more prominent in HPV-negative tumors in both the membrane (H-score 69.6 vs. 18.8; p = 0.003) and cytoplasm (H-score 59.2 vs. 17.7, p = 0.007). Cytoplasmic (H-score 61.7 vs. 11.7, p < 0.001) and membrane TF staining (H-score 71.7 vs. 15.0, p < 0.001) favored p16-negative tumors. The p53 status was more likely to be aberrant in the higher TF staining samples (cytoplasm H-score 61.7 vs. 18.3, p = 0.012; membrane H-score 67.5 vs. 20.3, p = 0.006). We observed an association with TROP2 staining and positive p16 status (membrane H-score 120.3 vs. 85, p = 0.052; cytoplasmic H-score 135 vs. 107.5, p = 0.041). We observed an association of TROP2 staining with positive LVI (membrane H-score 136.7 vs. 66.7, p = 0.014; cytoplasmic H-score 110 vs. 93.3, p = 0.04). We found no association between TF, TROP2, or nectin-4 staining with CSS or RFS; however, we suspect that this was due to our small sample size. Conclusions: Our results indicate that TF was expressed in the majority of advanced PSCC with enhanced expression among HPV-independent, p53-aberrant tumors and may represent a novel therapy target in advanced PSCC.


  • Open Access

    Bilateral Germ Cell Tumor of the Testis: Biological and Clinical Implications for a Stem Versus Genetic Origin of Cancers

    by Jamaal C. Jackson, Darren Sanchez, Aron Y. Joon, Marcos R. Estecio, Andrew C. Johns, Amishi Y. Shah, Matthew Campbell, John F. Ward, Louis L. Pisters, Charles C. Guo, et al.

    Germ cell tumors of the testis (GCTs) provide an ideal tumor model to investigate the cellular versus genetic origin of cancers. In this single institutional study, we evaluated 38 patients with bilateral GCT, including tumors that occurred simultaneously (synchronous) and those occurring at different times (metachronous). For nine of these patients, DNA was isolated from the right and left GCT to determine the genomic and epigenetic differences between tissues using whole-exome sequencing (WES) and reduced representation bisulfite sequencing (RRBS). We found that seminomas and non-seminomas are molecularly distinct based on DNA methylation and not due to synchronous or metachronous disease. In addition, we did not observe conservation of genetic mutations in right and left GCT in either synchronous or metachronous disease. Our data suggest a cellular origin for bilateral GCT.


  • Open Access

    Urethral Adenocarcinoma: A Rare Malignancy With Poor Oncologic Outcomes Despite Neoadjuvant Treatment and Consolidative Therapy

    by Landan P. MacDonald, Jamaal C. Jackson, Tarek I. Lawen, Ramez Kouzy, Lauren Colbert, Miao Zhang, Bogdan A. Czerniak, Curtis A. Pettaway, Kelly K. Bree

    Purpose: Primary urethral adenocarcinoma (PAC) is a rare malignancy associated with poor outcomes. There are 2 primary subtypes—clear cell adenocarcinoma (CCAC) and non–clear cell adenocarcinoma (nCCAC). In this study, we compare oncologic outcomes between CCAC vs nCCAC histological subtypes and describe differences in treatment modalities. Materials and Methods: We performed a retrospective review of patients diagnosed with PAC at our institution between 1993 to 2024. Survival analysis was stratified by histologic subtype (CCAC vs nCCAC) and primary treatment modality. Survival outcomes were stratified by patient age, neoadjuvant therapy (NAT), primary treatment modality, clinical stage, and histological subtype. Results: Of the 35 patients identified, the majority were female, were Black, and presented with locally advanced disease. Most of the patients were treated with radiotherapy (XRT) or surgical extirpation. There were no significant differences in clinical staging or histologic subtype between the 2 treatment modalities. Ten patients were treated with XRT, and 21 patients underwent primary surgical extirpation. Most of the patients received NAT. Locally advanced disease on final pathology was common for both histological subtypes. No patients were downstaged after surgical extirpation, despite nearly all receiving NAT. Survival was significantly better for CCAC vs nCCAC. There was no statistical difference in survival when comparing by treatment modality. Conclusions: PAC represents a rare, aggressive form of cancer. Favorable outcomes among the CCAC cohort may reflect a more favorable disease biology. Despite most of the patients receiving NAT, there were no patients with pathologic downstaging suggesting current neoadjuvant regimens are suboptimal and novel systemic strategies are needed for tumor downstaging to facilitate optimal local tumor control and improved oncologic outcomes.


  • Open Access

    Germ Cell Tumor of the Testis: Lethal Subtypes of a Curable Cancer

    by Jamaal C. Jackson, Darren Sanchez, Andrew C. Johns, Matthew T. Campbell, Ahmet M. Aydin, Neriman Gokden, Sanjay Maraboyina, Jason L. Muesse, John F. Ward, Louis L. Pisters, et al.

    Germ cell tumor of the testis (GCT) is a curable cancer even when it is widely metastatic; however, outcomes can differ based on tumor histology. Chemo-resistance in certain phenotypes, such as teratoma and yolk sac tumor, contributes to poor clinical outcomes in some patients with GCT. Despite this resistance to S-YSTemic therapy, many of these tumor subtypes remain amenable to surgical resection and possible cure. In this study, we report on a series of seven patients highlighting two chemo-resistant subtypes of nonseminomatous germ cell tumor (NSGCT), sarcomatoid yolk sac tumor (S-YST), and epithelioid trophoblastic tumor (ETT) for which early resection rather than additional salvage chemotherapy or high-dose intense chemotherapy might provide a superior clinical outcome and enhance cure rate.